Objective-Right ventricular (RV) failure is the leading cause of death in various cardiopulmonary diseases, including pulmonary hypertension. It is generally considered that the RV is vulnerable to pressure overload as compared with the left ventricle (LV). However, as compared with LV failure, the molecular mechanisms of RV failure are poorly understood, and hence therapeutic targets of the disorder remain to be elucidated. Thus, we aimed to identify molecular therapeutic targets for RV failure in a mouse model of pressure overload. Approach and Results-To induce pressure overload to respective ventricles, we performed pulmonary artery constriction or transverse aortic constriction in mice. We first performed microarray analysis and found that the molecules related to RhoA/Rho-kinase and integrin pathways were significantly upregulated in the RV with pulmonary artery constriction compared with the LV with transverse aortic constriction. Then, we examined the responses of both ventricles to chronic pressure overload in vivo. We demonstrated that compared with transverse aortic constriction, pulmonary artery constriction caused greater extents of mortality, Rho-kinase expression (especially ROCK2 isoform), and oxidative stress in pressure-overloaded RV, reflecting the weakness of the RV in response to pressure overload. Furthermore, mice with myocardial-specific overexpression of dominant-negative Rho-kinase showed resistance to pressure overloadinduced hypertrophy and dysfunction associated with reduced oxidative stress. Finally, dominant-negative Rho-kinase mice showed a significantly improved long-term survival in both pulmonary artery constriction and transverse aortic constriction as compared with littermate controls. Conclusion-These results indicate that the Rho-kinase pathway plays a crucial role in RV hypertrophy and dysfunction, suggesting that the pathway is a novel therapeutic target of RV failure in humans. (Arterioscler Thromb Vasc Biol. 2014;34:1260-1271.)
P ulmonary arterial hypertension is a fatal disease characterized by pulmonary vascular remodeling and resultant pressure overload to the right ventricle (RV) and RV failure. During the development of pulmonary arterial hypertension, the RV shows compensatory hypertrophy to maintain physiological wall stress, dilates with fibrotic changes, and ultimately results in functional failure. 1, 2 However, as compared with left ventricular (LV) failure, the molecular mechanisms of RV failure are poorly understood, and hence therapeutic targets of the disorder remain to be elucidated.
The origin of the RV is developmentally different from that of the LV. 3 Therefore, many structural differences exist between the RV and the LV and it is generally considered that the RV is vulnerable to pressure overload but is resistant to volume overload and vice versa for the LV. 4, 5 However, it remains to be examined how differently the RV responds to pressure overload as compared with the LV. To our knowledge, no studies have compared the differences in the responses to pressure overload between the 2 ventricles, with a special reference to underlying molecular mechanisms.
Pressure overload, such as systemic and pulmonary hypertension and stenotic valvular heart diseases, induces cardiac hypertrophy. 2, 6, 7 Although cardiac hypertrophy is basically a compensatory response to maintain wall stress, it eventually leads to cardiac dysfunction. 1, 2, 8, 9 The responses of cardiac tissues to pressure overload are mediated by various intracellular signaling pathways, including oxidative stress-mediated signaling pathways. [10] [11] [12] [13] We and others have previously demonstrated that the Rho-kinase pathway is substantially involved in LV pressure overload. 14, 15 Although most of the previous studies focused on the responses of LV to pressure overload, the molecular mechanisms of RV failure remain poorly understood, and hence the therapeutic targets of RV failure remain to be elucidated.
In the present study, we thus aimed to elucidate the molecular mechanisms of pressure overload-induced RV failure by comparing the responses of both ventricles in mice. For this purpose, we used pulmonary artery constriction (PAC) and transverse aortic constriction (TAC) to induce pressure overload in the RV and the LV, respectively.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Microarray Analysis
We first performed microarray analysis to examine the molecular signaling targets that could explain the difference in response to pressure overload between the RV (PAC) and the LV (TAC). By using the Ingenuity Pathway Analysis software, we found significant upregulation of integrin-β and integrinβ-related adhesion molecules (eg, α-actinin, talin, and vinculin) in the RV after PAC as compared with the LV after TAC ( Table 1) . The mechanotransduction through integrin may cause remodeling of actin cytoskeleton. 16, 17 Thus, the significant upregulation of integrin-β-related adhesion molecules potentially reflects the characteristics of the RV that is vulnerable to tensile compared with the LV. We also found significant upregulation of the Rho/Rho-kinase-related genes only in the RV after PAC ( Table 1 ). We also found that RhoA, a key molecule in the Rho/Rho-kinase pathway, was significantly upregulated in both PAC and TAC. Furthermore, ROCK1 and ROCK2 were differently regulated; ROCK2 was significantly increased only in the RV after PAC, whereas ROCK1 was unchanged in both ventricles (Table 1) . To further evaluate the role of these pathways, we confirmed the top 15 gene expressions of Table 1 by real-time PCR ( Figure II in the online-only Data Supplement). Consistent with the array data, the gene expressions in the RV after PAC showed significant increase as compared with the controls.
PAC and TAC Induces Oxidative Stress and Rho-Kinase Activation
To compare the responses of both ventricles to pressure overload, we performed PAC and TAC in wild-type mice. Importantly, mortality <24 hours was significantly higher in PAC compared with TAC, reflecting the vulnerability of the RV to acute pressure overload ( Figure 1A ). Oxidative stress is substantially involved in the development of cardiac hypertrophy and failure. [18] [19] [20] However, the time course and localization of oxidative stress induction in RV and LV after pressure overload remain to be examined. As evaluated by dihydroethidium staining at 24 hours after PAC and TAC in wild-type mice, we found rapid induction of oxidative stress in the loaded ventricles ( Figure 1B ; Figure IIIA in the onlineonly Data Supplement). PAC induced oxidative stress in the RV free wall, especially in the endocardium and epicardium, with no significant change in LV. In contrast, TAC induced oxidative stress in the LV wall, with no significant change in RV ( Figure 1B, arrows) .
We furthermore examined the changes in expressions of oxidative stress-related genes and Rho/Rho-kinase-related genes in the RV and LV at 24 hours after pressure overload by quantitative real-time PCR. Notably, oxidative stress genes (eg, p47phox and NOX2) were significantly upregulated in the RV after PAC and in the LV after TAC compared with the sham group ( Figure 1C ). Although there was no significant change in ROCK1 expression in loaded ventricles, RhoA and ROCK2 expressions were significantly upregulated in the loaded ventricles, which paralleled with the gene induction of p47phox and NOX2 ( Figure 1C ).
The roles of Rho-kinase (ROCK1 and ROCK2) in the LV and the RV after pressure overload remain to be elucidated. Thus, we next examined the time course and localization of ROCK1 and ROCK2 expression in the RV and the LV after PAC and TAC in wild-type mice by immunofluorescence staining ( Figure 2B ; Figure IIIB in the online-only Data Supplement). Interestingly, PAC rapidly and potently induced ROCK2 expression (but not ROCK1 expression) in the RV free wall, especially in the endocardium and free wall, at days 1 and 3, which was not evident in the LV ( Figure 2B , arrows). In contrast, TAC induced ROCK1 expression at days 3 and 7 and ROCK2 expression at day 7 in the vascular wall and perivascular area (Figure 2A , arrows). In addition, we examined the protein levels of ROCK1 and ROCK2 by Western blotting ( Figure IV in the online-only Data Supplement). Importantly, the protein levels of ROCK2 were upregulated at days 1 and 3 after PAC and at day 3 after TAC. Whereas, the protein levels of ROCK1 were gradually increased after PAC and TAC. Especially, the ROCK1 level at day 7 after TAC was significantly upregulated. We also found that the protein levels of ROCK1 (but not those of ROCK2) were significantly upregulated at 4 weeks after PAC and TAC. Furthermore, because the Rho-kinase staining patterns were similar to the localization of oxidative stress at day 1 after PAC ( Figure 1A) , we further examined the relationship between oxidative stress and Rho-kinase expressions by double-immunostaining. Interestingly, we noted the colocalizations of oxidative stress and ROCK2 (but not ROCK1) in the RV free wall at day 1 after PAC ( Figure VA and VB in the online-only Data Supplement).
We further examined the relationship between Rho-kinase expressions and CD45-positive inflammatory cell migration by double-immunostaining ( CD45-positive inflammatory cell migration. Consistently, we noted significant increase in inflammatory gene expressions (interleukin-6, interleukin-1β, and tumor necrosis factor-α) in the loaded ventricles, especially in the RV wall, at day 1 after PAC ( Figure VIB in the online-only Data Supplement),
suggesting that the induction of ROCK2 and inflammation in response to pressure overload is greater in the RV compared with the LV. Consistently, we noted significant increase in tissue hypoxia in the loaded ventricles, especially in the RV, at day 3 after PAC ( Figure 3A ; Figure VIIIA in B A C Figure 1 . Pressure overload-induced oxidative stress in the ventricles. A, Survival curves <24 h showed higher mortality rates after pulmonary artery constriction (PAC) compared with transverse aortic constriction (TAC; n=20 each). B, Representative pictures of dihydroethidium staining of right ventricle (RV) and left ventricle (LV) 24 h after PAC or TAC. PAC induced strong oxidative stress in the RV, especially in the endocardium and epicardium (arrows), with no significant change in the LV. In contrast, TAC induced mild oxidative stress in the LV (arrows), with no significant change in the RV. Scale bars, 200 μm. C, Relative mRNA expressions of oxidative stress markers (p47phox, NOX2, and NOX4), Rho and Rho-kinases (ROCK1 and ROCK2) in RV and LV 24 h after PAC or TAC compared with control (n=10-12). There were significant upregulations in p47phox and NOX2 expressions in the RV after PAC and in the LV after TAC, especially higher after PAC. NOX4 expression was not significantly altered. There were similar upregulations in RhoA and ROCK2 expressions in pressure-loaded ventricles, whereas ROCK1 expression was not significantly altered. the online-only Data Supplement). Both PAC and TAC progressively induced hypertrophic response ( Figure 3B ; Figure  VIIIB in the online-only Data Supplement), and in parallel to it, TAC increased the capillary density in the LV ( Figure 3C ; Figure VIIIC in the online-only Data Supplement). In contrast, PAC did not increase capillary density in the RV, causing myocardial ischemia in the loaded RV ( Figure 3A and 3C; Figure VIIIC in the online-only Data Supplement). These results suggest that the RV is more vulnerable to pressure overload and is more prone to myocardial ischemia as compared with the LV.
Crucial Role of Rho-Kinase for Cardiac Hypertrophy and Fibrosis in Pressure Overload
To further evaluate the role of myocardial Rho-kinase in response to pressure overload, we newly generated dominantnegative Rho-kinase (DN-RhoK) mice and examined the effects of PAC and TAC in those mice. In sham-operated mice, there was no difference in cardiac morphology between DN-RhoK mice and controls ( Figure 4A and 4B). Although PAC caused RV hypertrophy and fibrosis in both genotypes ( Figure 4A ), the extent of the increase in RV cross-sectional area and interstitial fibrosis was significantly less in DN-RhoK mice than in controls ( Figure 4B ). Interestingly, PAC significantly reduced LV cross-sectional area in controls ( Figure 4B ), suggesting an unloaded influence of PAC on the LV. Similarly, although TAC caused progressive LV hypertrophy and fibrosis in both genotypes ( Figure 4A ), the extent of the increase in LV cross-sectional area and interstitial fibrosis was significantly less in DN-RhoK mice than in controls ( Figure 4B ). Importantly, we found that the changes in hypertrophy and fibrosis were significantly greater in PAC compared with TAC ( Figure 4A and 4B). We further examined gene expressions of cardiac stress markers in both ventricles at 4 weeks after pressure overload ( Figure 4C ). The expressions of hypertrophic markers, such as atrial natriuretic factor and B-type natriuretic peptide, and fibrotic markers, such as collagen-I, III, and connective tissue growth factor, were significantly increased in loaded ventricles in both genotypes ( Figure 4C ). However, these increases in gene expressions in loaded ventricles were significantly less in DN-RhoK mice compared with controls ( Figure 4C ). The measurement of organ weights showed that PAC significantly increased RV weight and reduced LV plus septum weight at 4 weeks after operation ( Table II in the online-only Data Supplement). In contrast, TAC increased LV plus septum weight in controls, which was significantly less in DN-RhoK mice. We also found significant increase in liver weight ( Table  II in the online-only Data Supplement) and serum levels of liver enzymes (Table III in the online-only Data Supplement) after PAC compared with TAC, suggesting that PAC induced hepatic venous congestion. In contrast, TAC increased lung weight in both genotypes, suggesting lung congestion. However, these changes were significantly less in DN-RhoK mice compared with controls, suggesting a crucial role of Rhokinase in response to preload as well as pressure overload.
Involvement of Rho-Kinase in Impaired Cardiac Function and Survival in Pressure Overload
We next performed echocardiographic examination in DN-RhoK mice and controls at 4 weeks after PAC and TAC ( Figure 5A and 5B). In sham-operated mice, there was no difference in cardiac functions between DN-RhoK mice and controls ( Figure 5A and 5B). Notably, PAC caused RV dilatation and dysfunction in both genotypes with paradoxical motion of interventricular septum ( Figure 5A ). However, the increase in RV internal diameter in diastole and the decrease in RV fractional shortening were significantly less in DN-RhoK mice compared with controls ( Figure 5B ). In contrast, TAC caused LV dilatation and dysfunction in both genotypes. However, the increase in LV end-diastolic diameter and the decrease in LV fractional shortening were significantly less in DN-RhoK mice compared with controls ( Figure 5B ). TAC did not induce significant changes in RV internal diameter in diastole or RV fractional shortening ( Figure 5B ). The decrease in cardiac output was noted in both models, which was also significantly ameliorated in DN-RhoK mice compared with controls ( Figure 5B ).
To further examine cardiac functions after PAC and TAC, we performed catheter examinations at 4 weeks after operation ( Table 2) . DN-RhoK mice and controls showed equal increase in RV systolic blood pressure after PAC (Table 2 ). Furthermore, PAC significantly increased end-diastolic pressure in both ventricles of both genotypes; however, the increases were significantly less in DN-RhoK mice compared with controls. In contrast, DN-RhoK mice and controls showed equal increase in LV systolic blood pressure after TAC ( Table 2 ). Although TAC significantly increased RV systolic blood pressure in both genotypes, the increase was significantly less in DN-RhoK mice compared with controls. Furthermore, although TAC significantly increased end-diastolic pressure in both ventricles of both genotypes, these increases were significantly less in DN-RhoK mice compared with controls. Inconsistent with the hemodynamic results, we found significantly improved survival rates in DN-RhoK mice compared with controls in both PAC and TAC models ( Figure 5C ).
Rho-Kinase Activates Extracellular Signal-Regulated Kinase 1/2 and GATA4 in Loaded Ventricles
Pressure overload rapidly and potently induced oxidative stress and Rho-kinase upregulations in loaded ventricles (Figures 1  and 2) . To further examine the molecular responses to pressure overload, we examined myocardial Rho-kinase activity in loaded ventricles, as evaluated by the ratio of phosphorylated/total form of myosin-binding subunit ( Figure 6A ; Figure  IX in the online-only Data Supplement). In sham-operated mice, myocardial Rho-kinase activity of both ventricles was significantly less (~30%) in DN-RhoK mice compared with controls. PAC and TAC significantly activated Rho-kinase in loaded ventricles at 4 weeks after operation, and this activation was significantly less in DN-RhoK mice compared with controls in both PAC and TAC models. In contrast, interestingly, in the contralateral ventricles to pressure overload (LV after PAC and RV after TAC), we found no Rho-kinase activation. Extracellular signal-regulated kinase (ERK) 1/2 is activated in the hypertrophic responses to pressure overload. 21, 22 Because microarray analyses showed a significant increase in ERK and GATA4 expressions in response to pressure overload ( Table 1) , we examined the activity and nuclear translocation of p-ERK1/2 by immunostaining and Western blotting ( Figure 6B and 6C) . Interestingly, PAC and TAC increased the number of p-ERK1/2-positive nuclei in loaded ventricles ( Figure 6B ). Moreover, PAC and TAC activated ERK1/2 as assessed by the increase in p-ERK1/2 in the nuclear fraction in both genotypes ( Figure 6C ). However, this activation was significantly less in DN-RhoK mice compared with controls in both genotypes ( Figure 6C ). We further examined the activity and nuclear translocation of GATA4, the downstream mediator of ERK1/2, in loaded ventricles. Both PAC and TAC activated GATA4 as assessed by the ratio (p/t GATA4) in loaded ventricles in both genotypes ( Figure 6C ). However, this activation and nuclear translocation were significantly less in DN-RhoK mice compared with controls in both models ( Figure 6C ). Taken together, these results indicate that pressure overload by PAC and TAC activate and nuclear-translocate ERK 1/2 and GATA4 in loaded ventricles, in which Rho-kinase is substantially involved.
Rho-Kinase Causes Oxidative Stress in Loaded Ventricles
We further examined oxidative stress induction in DN-RhoK mice and controls at 4 weeks after PAC and TAC. Dihydroethidium staining showed that PAC and TAC significantly induced oxidative stress in RV and LV, respectively, compared with sham-operated mice ( Figure XA Data Supplement). Oxidative stress induces autophagy in the pathogenesis of heart failure. 23 Thus, we finally examined autophagy by Western blotting for the autophagy markers LC3A and p62/SQSTM-1 ( Figure XC and XD in the onlineonly Data Supplement). Importantly, both PAC and TAC significantly increased the levels of LC3A and p62/SQSTM-1 in loaded ventricles ( Figure XC and XD in the online-only Data Supplement), and this increase was significantly less in DN-RhoK mice, suggesting that Rho-kinase plays a crucial role in the induction of cardiac oxidative stress and autophagy.
Discussion
The major findings of the present study are as follows: (1) The extent of upregulation of the molecules downstream of integrin-β and RhoA, both of which augment oxidative stress in pressure-overloaded ventricles, was greater in PAC compared with TAC ( Figures XI and XII in the online-only Data Supplement). (2) ROCK2 was rapidly upregulated in the RV after PAC, colocalized with reactive oxygen species induction, whereas no significant change in ROCK1 expression was noted in pressure-overloaded ventricles. (3) Cardiac Rhokinase plays a crucial role for the activation of ERK1/2-GATA4 signaling in response to pressure overload. (4) Rho-kinase, especially ROCK2, is substantially involved in the molecular mechanisms of RV dysfunction and impaired survival in response to pressure overload. To the best of our knowledge, this is the first study that demonstrates the possible therapeutic importance of the Rho-kinase pathway in RV failure.
Specific Responses of the RV to Pressure Overload
Although the structural difference between the 2 ventricles is obvious, the fundamental functional difference between RV failure and LV failure remains unclear. 4, 5 Thus, we still have limited knowledge and strategy for the treatment of RV failure. In the present study, we addressed this fundamental issue by comparing the responses of both ventricles to pressure overload. Interestingly, there were significant differences in the induction pattern and localization of oxidative stress at 24 hours after pressure overload; PAC rapidly induced oxidative stress in the RV without significant change in the LV, whereas TAC slowly induced oxidative stress in the LV without significant change in the RV. Furthermore, ROCK2 was promptly upregulated in the RV after PAC, colocalized with reactive oxygen species induction. Interestingly, ROCK2-positive cardiomyocytes accompanied CD45-positive inflammatory cells, which would further augment oxidative stress and deteriorate the function of loaded ventricles (Figures XI and XII in the online-only Data Supplement). Thus, it is conceivable that the increased ROCK2 expression in the RV after PAC contributes, at least in part, to the vulnerability of the RV to pressure overload and the characteristic difference between the 2 ventricles. At present, we still have limited knowledge about the roles of ROCK1 and ROCK2 in the pathogenesis of RV and LV failure. However, recent reports revealed different roles of ROCK1 and ROCK2 in TAC-induced LV hypertrophy; ROCK1 plays an important role in fibrosis, whereas ROCK2 promotes hypertrophy. 24, 25 Thus, the prompt and potent upregulation of ROCK2 in the pressure-overloaded RV may reflect the crucial role of cardiac ROCK2 for hypertrophic responses. Several studies have reported that the RV expresses α-myosin heavy chain (V1) isoform to a greater extent compared with the LV, associated with a higher ATPase activity. 26, 27 This may link the pathogenetic role of ROCK2 in pressure-overloaded RV.
Regarding the upstream molecular mechanisms that augment ROCK2 expression in pressure-overloaded RV, the present microarray analysis revealed significant increases in integrin-β and its downstream mechanotransduction-related genes (eg, talin, vinculin, focal adhesion kinase, paxillin, and α-actinin) in the RV after PAC, but not in the LV after TAC. Mechanical stretch stimulates integrins, which activates RhoA/Rho-kinase signaling through Rho guanine nucleotide exchange factors. 28 Mechanotransduction through integrins leads to the activation of RhoA/Rho-kinase pathway, which induces hypertrophic gene activation. 16, 17 In contrast, mechanosensing by actin filaments causes actin cytoskeleton remodeling through small GTPases of the Rho/Rac/Cdc42 family. However, the detailed mechanisms are not fully elucidated as to the mechanoresponses and the link between the integrin, Rho guanine nucleotide exchange factors, and the downstream target, RhoA/Rho-kinase signaling. In the downstream mechanotransduction through integrin-β by pressure overload, the adhesion of α-actinin, talin, and vinculin to actin filaments may potentially contribute to the activation of FGD2 (Rho guanine nucleotide exchange factor) preferentially in the RV after PAC. 16 The present microarray analysis suggests that there is a special signaling cascade in the RV that connects the FGD2 and RhoA/ROCK2 signaling to the downstream of integrin-β, which may be the difference between the RV and the LV in response to mechanical stretch. Further studies on the roles of FGD2 and ROCK2 in RV pressure overload are needed to better understand the pathogenesis of RV failure.
Although it is widely known that cardiomyocytes can sense mechanical forces, it remains largely unknown how the forces are transmitted through the cytoskeleton. Moreover, the molecular differences between RV and LV cardiomyocytes remain to be elucidated. The present study demonstrates how forces applied to the cardiomyocytes are molecularly transduced and shared by cytoskeleton and crosslinker proteins (Figures XI and XII in the online-only Data Supplement). Taken together, these results suggest that ROCK2 plays a central role in the development of pressure overload-induced RV failure.
Pressure Overload Activates ROCK2 in Loaded Ventricles
We and others have previously demonstrated that the Rhokinase pathway is substantially involved in LV hypertrophy and failure in animals, in which oxidative stress is substantially involved. 14, 15 In the present study, we showed that the induction pattern and localization of oxidative stress was similar to those of ROCK2 in the RV after PAC. Thus, we evaluated the therapeutic effects of inhibition of cardiac Rho-kinase in PAC-induced RV hypertrophy and dysfunction in comparison with TAC-induced LV hypertrophy and dysfunction. Because many ROCK substrates are involved in cell death processes, 29 systemic deletion of Rho-kinase is embryonic-lethal. 30 Thus, we newly generated and used mice with myocardial-specific overexpression of DN-RhoK in the present study. In the present study, pressure overload induced oxidative stress and caused cardiac hypertrophy, fibrosis, and failure in both ventricles. Importantly, the DN-RhoK mice showed significantly fewer changes in pressure-loaded ventricles and significantly improved survival in both PAC and TAC models.
It is widely accepted that ERK1/2 plays a crucial role in myocardial hypertrophic responses to pressure overload. 21, 22 ERK1/2 signaling is associated with phosphorylation and activation of the cardiac prohypertrophic transcription factor GATA4. 31 Moreover, GATA4 regulates various gene expressions related to hypertrophy and heart failure. [32] [33] [34] Importantly, microarray analysis demonstrated that the expressions of both ERK and GATA4 were significantly upregulated in pressureoverloaded RV of wild-type mice. The present in vivo findings are in agreement with the previous in vitro studies. [35] [36] [37] It was previously reported that Rho-kinase contributes to the activation of ERK1/2 and GATA4 in myocardial hypertrophic response in vitro 35 and that Rho-kinase plays an important role in the nucleus translocation of p-ERK and GATA4 activation in vascular smooth muscle cells. 36, 37 Taken together, the present study provides the first evidence that the ERK1/2-GATA4 signaling pathway is downregulated in DN-RhoK mice compared with controls, resulting in attenuated myocardial hypertrophy and dysfunction in both PAC and TAC models (Figures XI and XII in the online-only Data Supplement).
In the process of pressure overload and cardiac failure, oxidative stress promotes induction of mitochondrial damage and autophagy. 20 Autophagy is required for adaptive response to hemodynamic stress and is increased in failing hearts, 38 in which GATA4 activation is critically involved. 39 In the present study, autophagy was significantly increased in pressureoverloaded ventricles by PAC and TAC in control mice, which was again significantly attenuated in DN-RhoK mice. Thus, Rho-kinase enhances autophagy in pressure-overloaded ventricles during compensatory hypertrophic response and dysfunction in both ventricles. In the present study, the inhibition of ROCK2 similarly ameliorated TAC-and PAC-induced cardiac hypertrophy and dysfunction, suggesting the importance of ROCK2 in both ventricles. However, to the best of our knowledge, the present study is the first that demonstrated the important role of Rho-kinase in the RV, suggesting the potential therapeutic importance of Rho-kinase in RV failure. A Rho-kinase inhibitor, fasudil, has been demonstrated to exert therapeutic effects in several cardiovascular diseases in animals and in humans. 40, 41 These results implicate the potential usefulness of Rho-kinase inhibitors for the treatment of patients with pressure overload-related disorders, such as hypertenstive heart disease and valvular heart disease. In addition, the development of isoform-specific ROCK inhibitors, especially ROCK2 inhibitors, may also be promising for the treatment of cardiac hypertrophy and failure. 15, 24 
Characteristics of RV Failure in Comparison With LV Failure
To our knowledge, there is a study demonstrating the different gene expressions after PAC and TAC in mice. 7 In the present study, we performed precise analyses, which further provided detailed characterizations of the difference between PAC and TAC. In the present study, the mortality of wild-type mice was better in TAC than in PAC in the acute phase, whereas the opposite was true in the chronic phase. In the present study, angiogenic response to pressure overload was less in the RV as compared with LV. Thus, it is possible that the extent of myocardial ischemia was greater in the RV than in the LV in the acute phase, as delineated with hypoxyprobe staining. Furthermore, the difference in the mortality could be explained by the present findings in PAC-induced RV failure. We found significant increase in liver weight after PAC, but not after TAC, a consistent finding with the previous report on hepatic venous congestion in PAC-induced RV failure. 7 Importantly, the increase in liver weight was significantly attenuated in DN-RhoK mice. In addition, PAC increased the serum levels of liver enzymes, as in the case with patients with severe RV failure. 42 Again, this was not the case for TAC. Interestingly, PAC significantly reduced LV weight, a consistent finding with the recent report that RV failure caused by pulmonary hypertension is associated with reduced LV free wall mass, probably because of negative ventricular-ventricular interaction and the long-term decrease in cardiac output. 43 Further studies are needed to elucidate the mechanisms involved in the alterations of the LV in response to RV pressure overload. Whereas, we found a significant increase in lung weight only in TAC, representative characteristics of lung remodeling and postcapillary pulmonary hypertension in LV failure. 8 One of the important characteristics of RV failure is the negative ventricular-ventricular interaction through the septum and epicardium with a resultant impairment of LV diastolic function. 44 Consistent with this report, we found an increase in LV diastolic pressure in the PAC model, suggesting LV diastolic dysfunction after PAC. Indeed, the RV is different from the LV structurally, geometrically, and mechanically. 2 In the present study, there were significant differences between PAC and TAC in terms of LV remodeling, capillary density, myocardial fibrosis, systolic blood pressure, lung and liver weights, and Rho-kinase activity, all of which may have affected the different mortality between the 2 models.
Study Limitations
Several limitations should be mentioned for the present study. First, pressure overload models with PAC or TAC may not fully represent the clinical features of RV and LV failure in humans. Thus, the present findings remain to be confirmed in other animal models of RV failure and finally in patients with the disorder. Second, although we ligated the aorta and pulmonary artery with the same needle (27G) for the same period (≈30 days), the extent of constriction of the arteries could have been incomparable because of the differences in their diameter, wall thickness, and physiology. Thus, we cannot eliminate the possibility that the difference between LV and RV responses could have been a technical issue. Third, because both ROCK1 and ROCK2 were inhibited in the present study by the overexpression of DN-RhoK, it remains to be determined which isoform is mainly responsible for the present findings, although the present results strongly suggest more important roles of ROCK2 as compared with ROCK1. These points also need to be examined in future studies using mice lacking respective isoform of Rho-kinase.
Conclusions
In the present study, we were able to demonstrate that the Rhokinase pathway (especially ROCK2-mediated one) plays a crucial role in RV hypertrophy and dysfunction, suggesting that the pathway is a novel therapeutic target of RV failure in humans.
